racemetirosine has been researched along with Idiopathic Parkinson Disease in 13 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
Excerpt | Relevance | Reference |
---|---|---|
"A crucial event in the pathogenesis of Parkinson's disease is the death of dopaminergic neurons of the nigrostriatal system, which are responsible for the regulation of motor function." | 1.46 | Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease. ( Khakimova, GR; Kozina, EA; Kucheryanu, VG; Ugrumov, MV, 2017) |
"Reserpine was injected in a dose of 10 mg/kg alone or with alpha-methyl-p-tyrosine (250 mg/kg) 1, 4 and 27." | 1.29 | Does reserpine induce parkinsonian rigidity? ( Lorenc-Koci, E; Ossowska, K; Wardas, J; Wolfarth, S, 1995) |
"Pretreatment with haloperidol and sulpiride blocked the effects induced by ciladopa." | 1.27 | Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug. ( Fields, JZ; Gordon, JH; Koller, WC; Perlow, MJ, 1986) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (38.46) | 18.7374 |
1990's | 2 (15.38) | 18.2507 |
2000's | 4 (30.77) | 29.6817 |
2010's | 2 (15.38) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Khakimova, GR | 1 |
Kozina, EA | 1 |
Kucheryanu, VG | 1 |
Ugrumov, MV | 1 |
Fuentes, R | 1 |
Petersson, P | 1 |
Siesser, WB | 1 |
Caron, MG | 1 |
Nicolelis, MA | 1 |
Lima, MM | 1 |
Andersen, ML | 1 |
Reksidler, AB | 1 |
Ferraz, AC | 1 |
Vital, MA | 1 |
Tufik, S | 1 |
Yoshimoto, Y | 1 |
Nakaso, K | 1 |
Nakashima, K | 1 |
Zhou, Z | 1 |
Kerk, S | 1 |
Meng Lim, T | 1 |
Gervas, JJ | 1 |
Muradás, V | 1 |
Bazán, E | 1 |
Aguado, EG | 1 |
de Yébenes, JG | 2 |
Diamond, BI | 1 |
Pasinetti, G | 1 |
Hitri, A | 1 |
Borison, RL | 1 |
Fahn, S | 2 |
Lorenc-Koci, E | 1 |
Ossowska, K | 1 |
Wardas, J | 1 |
Wolfarth, S | 1 |
Drukarch, B | 1 |
Jongenelen, CA | 1 |
Schepens, E | 1 |
Langeveld, CH | 1 |
Stoof, JC | 1 |
Pendleton, RG | 1 |
Parvez, F | 1 |
Sayed, M | 1 |
Hillman, R | 1 |
Jackson-Lewis, V | 1 |
Jorge, P | 1 |
Mena, MA | 1 |
Reiriz, J | 1 |
Koller, WC | 1 |
Fields, JZ | 1 |
Gordon, JH | 1 |
Perlow, MJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease[NCT03079310] | 15 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease.[NCT03526991] | 10 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | |||
STIMO-PARKINSON: Study on Feasibility of Targeted Epidural Spinal Stimulation (TESS) to Improve Mobility in Patients With Parkinson's Disease[NCT04956770] | 2 participants (Actual) | Interventional | 2021-06-14 | Active, not recruiting | |||
Effects of Repetitive Trans Spinal Magnetic Stimulation Associated With Treadmill Gait Training on Gait Disorders in Patients With Parkinson's Disease[NCT05938673] | 76 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | |||
Effects of Spinal Cord Stimulation on Gait in Patients With Parkinson´s Disease; a Randomized, Crossover, Double Blinded, Placebo-Controlled Study[NCT05148468] | 12 participants (Anticipated) | Interventional | 2021-11-30 | Active, not recruiting | |||
Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease[NCT02388204] | 20 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | |||
Efficacy of Repetitive Trans-spinal Magnetic Stimulation on Gait Abnormalities in Parkinson's Disease Patients: A Double-blinded Randomized Controlled Trial[NCT05271513] | 38 participants (Actual) | Interventional | 2023-01-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
13 other studies available for racemetirosine and Idiopathic Parkinson Disease
Article | Year |
---|---|
Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Methyltyrosine; Animals; Catecholamines; Early D | 2017 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopami | 2009 |
Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.
Topics: alpha-Methyltyrosine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulati | 2012 |
L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells.
Topics: alpha-Methyltyrosine; Animals; Cathepsin B; Cell Survival; Dopamine; Leupeptins; Levodopa; Parkinson | 2005 |
Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132.
Topics: alpha-Methyltyrosine; Animals; Cell Survival; Cysteine Proteinase Inhibitors; Dopamine; Leupeptins; | 2008 |
Effects of 3-OM-dopa on monoamine metabolism in rat brain.
Topics: alpha-Methyltyrosine; Animals; Blood-Brain Barrier; Brain; Carbon Radioisotopes; Dopamine; Levodopa; | 1983 |
Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain; Cholecystokinin; Dopamine; Drug Interactions; Extrapyramidal T | 1984 |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
Topics: Adult; Aged; alpha-Methyltyrosine; Carbidopa; Dopamine; Dopamine Antagonists; Drug Therapy, Combinat | 1983 |
Does reserpine induce parkinsonian rigidity?
Topics: Adrenergic Uptake Inhibitors; alpha-Methyltyrosine; Animals; Electromyography; Enzyme Inhibitors; Hi | 1995 |
Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Buthionine Sulfoximine; Cytoplasmic Granules; Dopamine; Glutathione; | 1996 |
Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; alpha-Methyltyrosine; alpha-Synuclein; A | 2002 |
Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Brain Diseases; Catheterization; Cerebral Ventricles; Disease Models, | 1988 |
Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug.
Topics: alpha-Methyltyrosine; Animals; Apomorphine; Body Temperature; Dogs; Dose-Response Relationship, Drug | 1986 |